We hypothesize that monomeric and oligomeric flavanols (MOF) have a beneficial effect on renal-endothelial function in the dietary management of T2D, as reflected by improvement of AER and renal-endothelial biomarkers.
ID
Bron
Verkorte titel
Aandoening
Diabetes type 2, microalbuminuria
Ondersteuning
MULTICENTER TRIAL: Erasmus Medical Center in Rotterdam and the community hospitals: Havenziekenhuis, IJsselland Ziekenhuis and Ikazia Ziekenhuis as well as GP-clinic Stichting Gezond op Zuid in Rotterdam.
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
Renal endothelial function will be measured before, during and after the intervention using albumin excretion rate in 24h urine (AER)
Achtergrond van het onderzoek
-
Doel van het onderzoek
We hypothesize that monomeric and oligomeric flavanols (MOF) have a beneficial effect on renal-endothelial function in the dietary management of T2D, as reflected by improvement of AER and renal-endothelial biomarkers.
Onderzoeksopzet
baseline - 6 weeks - 3 months
Onderzoeksproduct en/of interventie
During 3 consecutive months, the intervention group receives 200 mg of MOF once daily in the form of a commercially available Food for Special Medical Purposes (Endoclair), whereas the control group receives a placebo once a day
Publiek
Kirsten Berk
Rotterdam 3000 CA
The Netherlands
+31 (0)10 7033055
k.berk@erasmusmc.nl
Wetenschappelijk
Kirsten Berk
Rotterdam 3000 CA
The Netherlands
+31 (0)10 7033055
k.berk@erasmusmc.nl
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
• T2D
• Age 40-85 years
• Microalbuminuria in the previous 6 months (as microalbuminuria can change during time, results shouldn’t be older than 6 months), defined as:
- 30-300 mg albumin in a 24-hour urine sample
- or 3.5-35 mg albumin/mmol creatinine in females and 2.5-25 mg albumin/mmol creatinine in males in a urine portion.
This definition is derived from the Dutch national guidelines.
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
• Other types of diabetes mellitus as derived from the medical records
• Prior (less than 4 weeks before participating) or current use of any specific dietary supplementary products providing daily amounts of MOF of 25 mg/day or higher
• Anticoagulation medication
• Major health conditions: organ transplantation, untreated cancer, current chemotherapy or radiotherapy, acute or chronic organ failure
• Microalbuminuria due to other conditions than T2D
• Pregnancy or lactation during the trial
Opzet
Deelname
Voornemen beschikbaar stellen Individuele Patiënten Data (IPD)
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Geen registraties gevonden.
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
| Register | ID |
|---|---|
| NTR-new | NL4534 |
| NTR-old | NTR4669 |
| Ander register | METC Erasmus MC : MEC-2014-426 |